FDA Approves Daraxonrasib Expanded Access in Two Days — 60% Mortality Reduction in Pancreatic Cancer

Revolution Medicines submitted 4/28; FDA approved 4/30. Based on clinical data showing 60% mortality risk reduction versus chemotherapy in previously treated metastatic PDAC.